When Is a Stomach Issue Just a Stomach Issue? A Surgeon's Honest...
Dr Sanket Mehta explains which digestive symptoms deserve attention, how assessment works, and why screening...
Dr Sanket S Mehta
Dr Sanket S Mehta is a surgical oncologist and the Founder and CEO of SSO Cancer Hospitals. His clinical work focuses on gastrointestinal, hepatopancreatobiliary and gynaecological cancers, with a particular interest in peritoneal surface malignancies, which affect the lining of the abdomen. His areas of practice include cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, commonly known as CRS-HIPEC, alongside laparoscopic and robotic cancer surgery.
Dr Mehta has been in independent onco-surgical practice since 2011. He is Section Chief of the Division of Peritoneal Surface Oncology at Saifee Hospital, Mumbai, and has undertaken specialist clinical training in the USA, France, Italy and South Korea. He co-founded the Society of Peritoneal Surface Oncology of India and the Indian HIPEC Registry, and has contributed to research on peritoneal malignancies and cancer surgery.
Areas of expertise
- Peritoneal surface malignancies and CRS-HIPEC
- Gastrointestinal oncology
- Hepatopancreatobiliary surgery involving the liver, pancreas and bile ducts
- Gynaecological oncology
- Laparoscopic and robotic cancer surgery
Education and medical training
MBBS; MS in General Surgery.
Surgical oncology training at Tata Memorial Hospital, Mumbai.
Clinical and professional roles
- Founder and CEO, SSO Cancer Hospitals
- Section Chief, Division of Peritoneal Surface Oncology, Saifee Hospital, Mumbai
- Co-founder, Society of Peritoneal Surface Oncology of India and Indian HIPEC Registry
International clinical training
| Institution and location | Area of training |
| MedStar Washington Hospital Center, Washington DC, USA | CRS and HIPEC with Dr Paul Sugarbaker |
| CRLC Val d’Aurelle, Montpellier, France | Gastrointestinal oncology and CRS-HIPEC |
| Hôpital Saint-Eloi, CHU Montpellier, France | Digestive and minimally invasive surgery |
| Humanitas Hospital, Milan, Italy | Hepatopancreatobiliary surgery |
| St Mary’s Hospital, Catholic University of Korea, Seoul, South Korea | Laparoscopic and robotic colorectal surgery |
| Asan Medical Center, Seoul, South Korea | Minimally invasive hepatic surgery |
Selected research publications
Dr Mehta has contributed to the following research publications. His role in the 2025 consensus is recorded as a collaborator.
2025 Peritonectomy procedures for peritoneal surface malignancies: PSOGI-ESGO-ISSPP Lyon consensus. British Journal of Surgery.
2024 Perioperative outcomes and platinum resistant recurrence in patients undergoing systematic, protocol-based, total parietal peritonectomy during interval cytoreductive surgery for advanced ovarian cancer: results of the TORPEDO study. Journal of Gynecologic Oncology.
2020 The Pathologic Peritoneal Cancer Index (PCI) Strongly Differs From the Surgical PCI in Peritoneal Metastases Arising From Various Primary Tumors. Annals of Surgical Oncology.
2011 Results of two bi-institutional prospective studies using intraperitoneal oxaliplatin with or without irinotecan during HIPEC after cytoreductive surgery for colorectal carcinomatosis. Annals of Surgery.
Access to cancer care
Dr Mehta founded the Cancer Charity Trust in 2014 to help marginalised patients access subsidised cancer care.
Professional links
Articles by Dr Sanket S Mehta
5 min read
